Move will support economic growth, continues state’s investment in emerging technologies
CHICAGO – The Illinois Department of Commerce and Economic Opportunity (DCEO) today announced that Vetter Pharma International GmbH, a biopharmaceutical contract manufacturing organization headquartered in Ravensburg, Germany, will locate the company’s first domestic facility in Skokie, Illinois. The state’s $382,000 investment package will support a $12 million private investment by the company. This support is part of the state’s comprehensive regional economic development strategy to create jobs and build the Illinois economy.
“Illinois provides the ideal environment for technology to grow and thrive, mainly due to our tremendous assets that include an expansive network of state-of-the-art research institutions. I am pleased Vetter recognized the many opportunities that are available in Illinois when making their decision to locate in the state,” said DCEO Director Warren Ribley.
Using state-of-the-art technology, Vetter will be capable of aseptically filling very small quantities of products in the new facility, providing faster and more streamlined product delivery and customer service.
“The opening of this new cutting-edge Vetter Development Service (VDS) facility shows Vetter’s firm, strategic commitment to the North American market by bringing the state of the art technology to the heart of the U.S.,” said Peter Soelkner, Managing Director at Vetter. “The support VDS delivers throughout the entire product development cycle now can start earlier, and the proximity to our customers will contribute to streamlining the process and delivering the final product faster.”
The facility will be located in the Illinois Science & Technology Park, which serves as a central hub for Illinois science and technology companies. The park is located in close proximity to the nation’s top universities and research institutions, as well as teaching research hospitals.
With more than 200 academic, government and non-profit research institutions, and seven research and tech parks, Illinois has one of the largest concentrations of research facilities in the world.
“We welcome Vetter to the Illinois Science + Technology Park, where the company was able to take advantage of our specialized space which included clean room capabilities critical to manufacturing these types of products,” said Tom Prescott, general manager, Illinois Science + Technology Park, Forest City Science + Technology Group. “Vetter is the second international tenant to locate at the Park, reinforcing Chicago’s strong global position in the pharmaceutical and nanotechnology industries.”
The business investment package, administered by DCEO, includes Economic Development for a Growing Economy (EDGE) corporate income tax credits, which are based on job creation and Employer Training Investment Program (ETIP) job training funds that will help enhance the skills of its workforce.
Vetter is an independent international specialist in the aseptic filling of syringes, cartridges and vials. Based in Ravensburg, Germany, Vetter also produces its own injection systems, such as the Vetter Lyo-Ject® dual-chamber syringe. With about 1,900 employees worldwide, Vetter holds nearly 140 patents and has longstanding experience in handling client products and processes approved by the FDA, the EMEA and other authorities.